Zhi Tong Cai Jing·2025-12-15 13:02Core Viewpoint - Fosun Pharma is focusing on unmet clinical needs in the central nervous system treatment area by investing a total of 1.41 billion yuan in Green Valley Pharmaceutical to enhance its innovative product pipeline and market layout [1] Group 1: Investment Details - Fosun Pharma's subsidiary plans to invest 143 million yuan to acquire 20.15 million yuan of registered capital from existing shareholders [1] - An additional investment of 1.27 billion yuan will be made to subscribe for 200.87 million yuan of new registered capital [1] Group 2: Shareholder Arrangements - The target company will first pay relevant buyback amounts to certain employees, with existing shareholders transferring 8.67 million yuan of registered capital to a newly established SPV at a nominal price [2] - After the completion of the acquisition, Fosun Pharma will hold a combined 53% stake in the target company, which will be included in the consolidated financial statements [2] Group 3: Product Information - The target group specializes in the research, production, and sales of drugs for neurodegenerative diseases, with its main product, Ganluo Sodium Capsule, conditionally approved for Alzheimer's treatment [3] - The drug has shown significant cognitive improvement in patients with mild to moderate Alzheimer's disease, particularly in moderate cases, based on clinical trial results [3] - Commercial production of the drug is currently on hold due to the expiration of its registration certificate, pending the completion of post-marketing confirmatory clinical trials [3]